← Back to Search

Radiation Therapy

Group 2: Peripherally Located Chest Wall Adjacent Tumors for Non-Small Cell Lung Cancer

N/A
Waitlist Available
Led By Matthew Harkenrider, MD
Research Sponsored by Loyola University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 104 weeks
Awards & highlights

Study Summary

This trial will test the hypothesis that SBRT results in a higher rate of tumor control and longer overall survival compared to EBRT in medically inoperable early-stage NSCLC patients.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~104 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 104 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Toxicity Evaluation
Secondary outcome measures
Disease Specific Outcomes

Trial Design

3Treatment groups
Experimental Treatment
Group I: Group 3: Centrally Located TumorsExperimental Treatment1 Intervention
Centrally Located Tumors - SBRT
Group II: Group 2: Peripherally Located Chest Wall Adjacent TumorsExperimental Treatment1 Intervention
Peripherally Located Chest Wall Adjacent Tumors - SBRT
Group III: Group 1: Peripherally Located TumorsExperimental Treatment1 Intervention
Peripherally Located Tumors - SBRT

Find a Location

Who is running the clinical trial?

Loyola UniversityLead Sponsor
156 Previous Clinical Trials
30,893 Total Patients Enrolled
Matthew Harkenrider, MDPrincipal InvestigatorEdward Hines Jr. VA Hospital
1 Previous Clinical Trials
24 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
International Journal of Radiation Oncology*Biology*PhysicsJournal
Stereotactic Body Radiation Therapy for Early-stage Non–small-cell Lung Carcinoma: Four-year Results of a Prospective Phase II Study
Fakiris, Achilles J., Ronald C. McGarry, Constantin T. Yiannoutsos, Lech Papiez, Mark Williams, Mark A. Henderson, and Robert Timmerman. 2009. “Stereotactic Body Radiation Therapy for Early-stage Non–small-cell Lung Carcinoma: Four-year Results of a Prospective Phase II Study”. International Journal of Radiation Oncology*biology*physics. Elsevier BV. doi:10.1016/j.ijrobp.2008.11.042.
American Journal of Clinical OncologyJournal
Stereotactic Body Radiation Therapy for Unbiopsied Early-stage Lung Cancer
Harkenrider, Matthew M., Matthew H. Bertke, and Neal E. Dunlap. 2014. “Stereotactic Body Radiation Therapy for Unbiopsied Early-stage Lung Cancer”. American Journal of Clinical Oncology. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/coc.0b013e318277d822.
International Journal of Radiation OncologyBiologyPhysicsJournal
Radiotherapy Alone for Medically Inoperable Stage I Non-small–cell Lung Cancer: The Duke Experience
Sibley M.D., Gregory S., Timothy A. Jamieson M.D., Ph.D., Lawrence B. Marks M.D., Mitchell S. Anscher M.D., and Leonard R. Prosnitz M.D.. 1998. “Radiotherapy Alone for Medically Inoperable Stage I Non-small–cell Lung Cancer: The Duke Experience”. International Journal of Radiation Oncologybiologyphysics. Elsevier BV. doi:10.1016/s0360-3016(97)00589-0.
Lung CancerJournal
The Role of Radiotherapy in Treatment of Stage I Non-small Cell Lung Cancer
Qiao, Xueying, Owe Tullgren, Ingmar Lax, Florin Sirzén, and Rolf Lewensohn. 2003. “The Role of Radiotherapy in Treatment of Stage I Non-small Cell Lung Cancer”. Lung Cancer. Elsevier BV. doi:10.1016/s0169-5002(03)00152-1.
All > Non Small Cell Lung Cancer > Nsclc
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top